JoseE.NajeraMD

Oncology • Lawton, OK

Cancer centers of Southwest Oklahoma

Join to view full profile

Dr. Najera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Najera's full profile

Already have an account?

Office
104 NW 31st St
Lawton, OK 73505
Phone+1 580-536-2121

Fax+1 580-536-2150

Summary

Dr. Jose Najera is an oncologist in Lawton, OK and is affiliated with Cancer Centers of Southwest Oklahoma. He received his medical degree from Universidad de Monterrey and has been in practice 10 years. He specializes in hematology and medical oncology. He is the Principal Investigator for CCSWOK.

Education & Training

Orlando HealthFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2007 - 2010
Universidad de MonterreyClass of 2007

Certifications & Licensure

OK State Medical License 2013 - 2025
TX State Medical License 2012 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2013

Publications & Presentations

PubMed

222 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost
The New England Journal of Medicine. 2023-03-02
3 citations
Cohort study with patients older than 80 years with stage 5 chronic kidney failure on hemodialysis vs conservative treatment: Survival outcomes and use of healthcare r...
Alicia García Testal, Rafael García Maset, Victoria Fornés Ferrer, Antonio José Cañada Martínez, Sonia Fernández Fandos
Therapeutic Apheresis and Dialysis. 2021-02-01
6 citations
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera
Clinical Breast Cancer. 2021-10-28

Committees

President, Oklahoma Society of Clinical Oncology 2018 - Present

Research History

Principal Investigator2017 - Present

Other Languages

Spanish